Contineum Therapeutics, Inc. Public Float
Contineum Therapeutics, Inc. (CTNM) had Public Float of $102.10 million as of 2025-06-30, per its 10-K filed 2026-03-05.
Financial Statements › Notes › Cover Page
dei:EntityPublicFloat · last filed 2026-03-05
- 2025-06-30: Entity Public Float $102.10M.
- 2024-06-28: Entity Public Float $356.00M.
| Period end | Entity Public Float |
|---|---|
| 2025-06-30 | $102.10M 10-K · filed 2026-03-05 |
| 2024-06-28 | $356.00M 10-K · filed 2025-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |